AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

News

Author: Parkinson's Life editorsPublished: 31 August 2017

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

AstraZeneca and Takeda lead

AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after agreeing a deal to co-develop an early-stage medicine for Parkinson’s disease.

The drug, MEDI1341, is an antibody treatment and is due to enter phase I clinical trials later this year.

Mene Pangalos, executive vice president of AstraZeneca, said: “By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach to support the treatment of people with Parkinson’s disease around the world.”

The two companies will share future development and commercialisation costs for MEDI1341 equally, in addition to future revenues.

Go Back

Share this story

Comments


Related articles


Carer's Week lead image

Carers' Corner

10 shocking facts that show what it’s like to be a carer

Highlighting the issues faced by carers throughout Europe

READ MORE

Interviews

“It is time for us to act more aggressively to end Parkinson’s”

Four Parkinson’s experts share their plan to end Parkinson’s

READ MORE
Brain scan

Resources & Tools

Parkinson’s podcast: ‘Parkinson’s Plus’ conditions

A look at the rare conditions often mistaken for Parkinson’s

READ MORE